Abstract
Background: Targeting the epidermal growth factor receptor (EGFR) improved radiotherapy outcome by 10-15% in head and neck tumors (HNSCC). We tested the therapeutic benefits of co-targeting EGFR and insulin-like growth factor-1 receptor (IGF-1R) to further enhance tumor response to radiation. Materials and Methods: Mice bearing FaDu tumor xenografts were treated with ganitumab (previously known as AMG479, an anti-IGF-1R antibody), panitumumab (an anti-EGFR antibody), or both in combination with fractionated doses of radiation. Tumor growth delay and tumor cure/recurrence served as endpoints. Results: The best tumor growth delay was achieved when ganitumab and panitumumab were given concurrently with radiation. Tumor cure/recurrence studies showed that combining ganitumab, panitumumab and radiation resulted in significantly higher radiocurability rates than use of either of the agents given with radiation. Conclusion: These findings provide the rationale for clinical testing of the combination of ganitumab and panitumumab for the treatment of HNSCC.
Original language | English (US) |
---|---|
Pages (from-to) | 3029-3035 |
Number of pages | 7 |
Journal | Anticancer research |
Volume | 32 |
Issue number | 8 |
State | Published - Aug 2012 |
Keywords
- EGFR
- FaDu cells
- Head and neck cancer
- IGF-1R
- Radiation
- Tumor response
ASJC Scopus subject areas
- Oncology
- Cancer Research